Literature DB >> 12215732

Prevention of and medical therapy for atrial arrhythmias in heart failure.

A U Khand1, J G F Cleland, P C Deedwania.   

Abstract

A large proportion of heart failure patients suffer from atrial arrhythmias, prime amongst them being atrial fibrillation (AF). Ventricular dysfunction and the syndrome of heart failure can also be a concomitant pathology in up to 50% of patients with AF. However this association is more than just due to shared risk factors, research from animal and human studies suggest a causal relationship between AF and heart failure. There are numerous reports of tachycardia-induced heart failure where uncontrolled ventricular rate in AF results in heart failure, which is reversible with cardioversion to sinus rhythm or ventricular rate control. However the relationship extends beyond tachycardia-induced cardiomyopathy. Optimal treatment of AF may delay progressive ventricular dysfunction and the onset of heart failure whilst improved management of heart failure can prevent AF or improve ventricular rate control. Prevention and treatment of atrial arrhythmias, and in particular atrial fibrillation, is therefore an important aspect of the management of patients with heart failure. This review describes the incidence and possible predictors of AF and other atrial arrhythmias in patients with heart failure and discusses the feasibility of primary prevention. The evidence for the management of atrial fibrillation in heart failure is systematically reviewed and the strategies of rate versus rhythm control discussed in light of the prevailing evidence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215732     DOI: 10.1023/a:1020097728178

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  113 in total

1.  Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation.

Authors:  A Capucci; G Q Villani; D Aschieri; A Rosi; M F Piepoli
Journal:  Eur Heart J       Date:  2000-01       Impact factor: 29.983

2.  UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells.

Authors:  M Gwilt; J E Arrowsmith; K J Blackburn; R A Burges; P E Cross; H W Dalrymple; A J Higgins
Journal:  J Pharmacol Exp Ther       Date:  1991-01       Impact factor: 4.030

3.  The alternation between atrial flutter and atrial fibrillation.

Authors:  P A Tunick; L McElhinney; T Mitchell; I Kronzon
Journal:  Chest       Date:  1992-01       Impact factor: 9.410

Review 4.  Epidemiology and mechanism of atrial fibrillation and atrial flutter.

Authors:  A J Camm; O A Obel
Journal:  Am J Cardiol       Date:  1996-10-17       Impact factor: 2.778

5.  Atrial fibrillation begets trouble.

Authors:  J E Waktare; A J Camm
Journal:  Heart       Date:  1997-05       Impact factor: 5.994

6.  Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.

Authors:  R H Falk; A Pollak; S N Singh; T Friedrich
Journal:  J Am Coll Cardiol       Date:  1997-02       Impact factor: 24.094

7.  Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation.

Authors:  F D Murgatroyd; S M Gibson; X Baiyan; S O'Nunain; J D Poloniecki; D E Ward; M Malik; A J Camm
Journal:  Circulation       Date:  1999-06-01       Impact factor: 29.690

Review 8.  Management of atrial fibrillation in the setting of heart failure.

Authors:  H J Crijns; M P Van den Berg; I C Van Gelder; D J Van Veldhuisen
Journal:  Eur Heart J       Date:  1997-05       Impact factor: 29.983

9.  Prediction of paroxysmal atrial fibrillation in patients with congestive heart failure: a prospective study.

Authors:  T Yamada; M Fukunami; T Shimonagata; K Kumagai; H Ogita; Y Asano; A Hirata; H Masatsugu; N Hoki
Journal:  J Am Coll Cardiol       Date:  2000-02       Impact factor: 24.094

10.  Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone.

Authors:  R G Tieleman; A T Gosselink; H J Crijns; I C van Gelder; M P van den Berg; P J de Kam; W H van Gilst; K I Lie
Journal:  Am J Cardiol       Date:  1997-01-01       Impact factor: 2.778

View more
  2 in total

Review 1.  Rate control in atrial fibrillation: choice of treatment and assessment of efficacy.

Authors:  Giuseppe Boriani; Mauro Biffi; Igor Diemberger; Cristian Martignani; Angelo Branzi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Role of antithrombotic agents in heart failure.

Authors:  John G F Cleland; Saqib Mumtaz; Luca Cecchini
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.